The global aesthetic injectable market was valued at approximately USD 10.99 billion in 2023 and is projected to reach USD 24.13 billion by 2030, growing at a compound annual growth rate (CAGR) of 12.1% from 2024 to 2030. Key factors driving this market include increasing awareness and acceptance of aesthetic treatments, the launch of innovative injectable products for various applications, and advancements in technology.
According to the American Society of Plastic Surgeons, Botulinum Toxin (Botox) treatment was the most common noninvasive procedure in the U.S. in 2022, with over 7.4 million individuals receiving Botox injections. As people become more informed and proactive about using aesthetic injectables to enhance their appearance and address cosmetic concerns, the market continues to expand. Additionally, the growing global geriatric population is a significant contributor to market growth. For instance, Australia's 2023 Intergenerational Report predicts that by 2050, the population aged 65 to 84 will more than double, while those aged 85 and over are expected to quadruple. This demographic shift is leading to an increase in specialized clinics catering to older individuals.
As major economies experience demographic changes due to a rapidly aging population, the demand for cosmetic solutions to combat visible signs of aging is rising. This has resulted in a notable increase in the demand for botulinum toxin and aesthetic injectables that effectively address wrinkles, fine lines, and other age-related concerns.
Key Market Trends & Insights
- Regional Dominance: North America led the market with a revenue share of 39.3% in 2023, driven by a growing population aged 25 to 65 years, who are increasingly concerned about skin aging, including laxity, wrinkles, and dark spots. Rising disposable income in the region is also expected to support market growth in the coming years.
- U.S. Market Leadership: The aesthetic injectable market in the U.S. accounted for the largest share at 87.22% in 2023 within North America, attributed to high demand for advanced laser scar treatment instruments. According to the International Society of Aesthetic Plastic Surgery (ISAPS), approximately 4,556,970 nonsurgical injectable procedures were performed in the U.S. in 2022, with 3,945,282 involving Botox fillers and 521,169 involving HA fillers.
- Product Segment: The botulinum toxin (Botox) segment held the largest market share of 45.75% in 2023. Botulinum Toxin Type A (BoNTA) is a purified neurotoxic protein that prevents muscle contraction, effectively reducing facial wrinkles and treating conditions like crow’s feet, frown lines, forehead furrows, and neck skin bands.
- Application Focus: The facial line correction segment held the largest market share in 2023 and is projected to experience the fastest CAGR during the forecast period. The rising popularity of noninvasive cosmetic procedures, such as dermal fillers and Botox injections, to treat facial lines and wrinkles is a key driver of this segment’s growth.
- End-Use Segment: The medical spas segment held the largest market share in 2023 and is expected to see the fastest CAGR during the forecast period. This growth is attributed to increasing consumer demand for non-invasive cosmetic procedures, technological advancements leading to more effective treatments, and a heightened focus on self-care and wellness.
Order a free sample PDF of the Aesthetic Injectable Market Intelligence Study, published by Grand View Research.
Market Size & Forecast
- 2023 Market Size: USD 10.99 Billion
- 2030 Projected Market Size: USD 24.13 Billion
- CAGR (2024-2030): 12.1%
- North America: Largest market in 2023
- Asia Pacific: Fastest growing market
Key Companies & Market Share Insights
Key players in the aesthetic injectable market include Ipsen Pharma, AbbVie, Inc., Merz GmbH and Co. KGaA, Galderma, and Sinclair Pharma. These companies drive innovation and quality through strategic initiatives, including research and development investments and a focus on advanced manufacturing technologies.
- Ipsen Pharma: A biopharmaceutical company based in France, focusing on transformative medicines. Ipsen develops and markets pharmaceuticals in oncology, neurology, and rare disorders, having evolved from a consumer wellness company to a specialized care provider contributing significantly to its revenue.
- AbbVie, Inc.: A U.S.-based pharmaceutical company offering advanced aesthetic solutions along with products for neurology, eye care, gastroenterology, anti-infectives, and women’s health. AbbVie serves physicians, healthcare providers, and patients, with a presence in over 100 countries.
Key Players
- Ipsen Pharma
- AbbVie, Inc.
- Merz GmbH and Co. KGaA
- Galderma
- Prollenium Medical Technologies, Inc.
- Suneva Medical, Inc.
- Sinclair Pharma
- Medytox, Inc.
- Revance Therapeutics, Inc.
Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.
Conclusion
The aesthetic injectable market is on a robust growth trajectory, driven by increasing awareness and acceptance of aesthetic treatments, coupled with demographic shifts that emphasize the need for effective cosmetic solutions. As the aging population grows and technological advancements continue to emerge, the demand for aesthetic injectables is expected to rise significantly. Companies that innovate and adapt to consumer needs will likely thrive in this competitive landscape.
